The estimated Net Worth of Rahul Singhvi is at least 2.16 百万$ dollars as of 1 July 2009. Rahul Singhvi owns over 258,334 units of Novavax stock worth over 1,390,048$ and over the last 20 years Rahul sold NVAX stock worth over 772,419$.
Rahul has made over 2 trades of the Novavax stock since 2007, according to the Form 4 filled with the SEC. Most recently Rahul sold 258,334 units of NVAX stock worth 772,419$ on 1 July 2009.
The largest trade Rahul's ever made was selling 258,334 units of Novavax stock on 1 July 2009 worth over 772,419$. On average, Rahul trades about 16,215 units every 42 days since 2005. As of 1 July 2009 Rahul still owns at least 113,104 units of Novavax stock.
You can see the complete history of Rahul Singhvi stock trades at the bottom of the page.
Rahul's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Over the last 23 years, insiders at Novavax have traded over 136,088,511$ worth of Novavax stock and bought 2,908,869 units worth 5,634,467$ . The most active insiders traders include David M Mott、Rajiv I. Modi、Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of 907,678$. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth 8,050$.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: